A carregar...
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma
Aim: Gemcitabine is a frontline agent for locally-advanced and metastatic pancreatic ductal adenocarcinoma (PDAC), but neither gemcitabine alone nor in combination produces durable remissions of this tumor type. We developed three PDAC patient-derived xenograft (PDX) models with gemcitabine resistan...
Na minha lista:
| Publicado no: | Cancer Drug Resist |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
OAE Publishing Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7561044/ https://ncbi.nlm.nih.gov/pubmed/33073205 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20517/cdr.2020.35 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|